PRESS RELEASE published on 07/11/2024 at 07:05, 4 months 10 days ago Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business Heidelberg Pharma AG reports positive preliminary efficacy data for HDP-101 in multiple myeloma clinical trial. Key events include AACR Meeting presentation & FDA Orphan Drug Designation Clinical Trial HDP-101 Heidelberg Pharma AG AACR Meeting FDA Orphan Drug Designation
BRIEF published on 06/21/2024 at 11:21, 5 months ago Heidelberg Pharma rend compte des résultats de l'Assemblée générale annuelle 2024 Actionnaires Resolutions Heidelberg Pharma Actualités Financières AGA 2024
BRIEF published on 06/21/2024 at 11:21, 5 months ago Heidelberg Pharma Reports on the Results of the Annual General Meeting 2024 Shareholders Financial News Resolutions Heidelberg Pharma AGM 2024
PRESS RELEASE published on 06/21/2024 at 11:16, 5 months ago Heidelberg Pharma reports on the results of the Annual General Meeting 2024 Heidelberg Pharma AG reports on the results of the Annual General Meeting 2024, including approval of resolutions and shareholder attendance Shareholders Voting Results Annual General Meeting 2024 Cancer Therapy Heidelberg Pharma AG
BRIEF published on 06/18/2024 at 13:52, 5 months 3 days ago Heidelberg Pharma AG Announces Updated Guidance for 2024 Revenue Forecast Financial Guidance Biotech Heidelberg Pharma AG Operating Expenses
BRIEF published on 06/18/2024 at 13:52, 5 months 3 days ago Heidelberg Pharma AG annonce des prévisions mises à jour pour 2024 Conseils Financiers Prévisions De Revenus Heidelberg Pharma SA Biotechnologies Dépenses De Fonctionnement
PRESS RELEASE published on 06/18/2024 at 13:47, 5 months 3 days ago EQS-Adhoc: Heidelberg Pharma AG announces updated guidance Heidelberg Pharma AG updates guidance for fiscal year 2024, lowering sales expectations due to delays and adjusting operating expenses. Financing secured until mid-2025 with potential expansion until end of 2026 Financial Year 2024 Heidelberg Pharma AG Operating Expenses Sales Expectations Updated Guidance
BRIEF published on 05/23/2024 at 09:17, 5 months 29 days ago Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024 Cancer Treatment Conférences Heidelberg Pharma HDP-101 ADCs
BRIEF published on 05/23/2024 at 09:17, 5 months 29 days ago Heidelberg Pharma participera et présentera des conférences scientifiques de premier plan à venir en mai et juin 2024 Conférences Traitement Du Cancer Heidelberg Pharma HDP-101 ADC
PRESS RELEASE published on 05/23/2024 at 09:12, 5 months 29 days ago Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024 Heidelberg Pharma AG to participate and present at leading scientific conferences in May and June 2024, showcasing innovative ADC technology platforms for cancer treatment Cancer Treatment ADC Technology Heidelberg Pharma AG Scientific Conferences Clinical Stage Biotech
Published on 11/21/2024 at 16:01, 27 minutes ago Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 28 minutes ago Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 28 minutes ago Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 15:30, 58 minutes ago CLS Health Opens New Comprehensive Care Clinic in Sugar Creek
Published on 11/21/2024 at 15:24, 1 hour 4 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 1 hour 5 minutes ago Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 1 hour 6 minutes ago Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 11/21/2024 at 06:58, 9 hours 30 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 30 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 30 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 20 hours 21 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 21 hours 8 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
